AlphAIAlphAI — Financial news for AI agents
pharmexec.comSEP 282 min read$MRK

Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch

Merck licensed preclinical KRAS G12D inhibitor SPR2015 from SciBrunch for $400M upfront, with potential total value of $2.13B. The drug showed efficacy in colorectal cancer models. Merck will record a $400M pre-tax charge in Q3 2026. SciBrunch focuses on RAS pathway therapies.

Original reporting
pharmexec.com
Published Sep 28, 2026, 5:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 7:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch — source image
Source · pharmexec.com
Decision brief

The 30-second read

$MRKBullishMed
01

Why it matters

The licensing deal could enhance Merck's long‑term pipeline value while creating a near‑term earnings charge.

02

Market read

A material licensing agreement for a preclinical KRAS inhibitor, likely to affect Merck's stock and oncology sector sentiment.

03

What to watch

Potential regulatory hurdles for KRAS G12D inhibitors and competition from other biotech pipelines.

Relevance 9/10Novelty 9/10Timing: immediate

Background

Merck is expanding its oncology portfolio amid growing interest in KRAS‑targeted therapies.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck signed an exclusive global license for the preclinical KRAS G12D inhibitor SPR2015, paying $400M upfront and recording a $0.13 per share charge.

Expected impact

likely modest upside as the market prices in the $400M upfront payment and future milestone potential.

Evidence & confidence

Large upfront cash outlay and $2.13B potential total value constitute a material corporate event for a large‑cap pharma.

Market effects

Sector

strengthens the oncology/biotech sector by adding a promising KRAS‑targeted candidate.

Regional

impacts US pharma equities and may influence peer valuations.

Global

adds to global precision‑oncology pipeline activity, relevant for investors worldwide.

Counterpoint

What could challenge this read

The preclinical stage may delay any near‑term revenue impact, and the $400M charge could pressure short‑term earnings.

Key entities

  • Company
    Merck

    US‑listed pharmaceutical giant (ticker MRK).

  • Company
    SciBrunch Therapeutics

    Private biotech developer of SPR2015.

Read at source← All news

Related articles

SEP 28
$MRKHighAI 8/10

Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy

Merck (MRK) and Daiichi Sankyo withdrew their FDA filing for ifinatamab deruxtecan, a lung cancer therapy, due to insufficient data. They continue evaluating it in late-stage studies. MRK's shares are up 41% year-to-date. This is the second withdrawal under their 2023 partnership.

zacks.com2 min
SEP 28
$MRKMed

Merck’s Forward P/E Nearly Doubled to 17x in a Year. Here’s What Its Pipeline Must Deliver by 2030

Merck (MRK) and Daiichi Sankyo withdrew a U.S. approval application for their investigational cancer drug, citing insufficient data. Merck's stock is at $148.74, with a mid-target of $166 and a potential 12% total return. The company's pipeline is estimated to deliver $70B+ by the mid-2030s, but recent setbacks highlight risks. Analysts' FY2030 revenue estimates have risen to around $76B.

tikr.com3 min
SEP 28
$MRKMedAI 9/10

Merck closes SciBrunch KRAS licence for up to US$2.13B

Merck & Co. has closed a licence agreement with SciBrunch Therapeutics for worldwide rights to a preclinical KRAS G12D cancer drug, SPR2015, for up to $2.13B, including a $400M upfront payment. The deal includes potential milestone payments tied to development and commercialization. Merck shares traded at $147.79 on Sept. 28, with a $400M pre-tax charge expected in Q3 2026 results.

mugglehead.com2 min
SEP 28
$MRKHighAI 9/10

Merck & Co and SciBrunch sign deal worth up to $2.13 billion

Merck & Co (MRK) has signed a global license agreement with SciBrunch Therapeutics for the preclinical oral KRAS G12D (ON) inhibitor SPR2015. Merck will pay $400 million upfront and up to $2.13 billion in total, including milestone payments, for exclusive worldwide rights to develop, manufacture, and commercialize the drug.

thepharmaletter.com2 min
SEP 28
$ABBVHighAI 8/10

AbbVie wins FDA nod for Parkinson’s pill

The FDA approved AbbVie's Parkinson's pill, tavapadon, to be sold as Juvmo. The drug is part of its $8.7 billion acquisition of Cerevel Therapeutics. AbbVie expects over $5 billion in combined sales from its Parkinson's portfolio, though analysts caution uptake may be gradual due to Medicare coverage negotiations.

statnews.com2 min